Characterization_of_in_vitro_chemosensitivity_of_perioperative_human_ovarian_malignancies_by_adenosine_triphosphate_chemosensitivity_assay._We_report_the_in_vitro_chemosensitivity_of_primary_and_recurrent_human_ovarian_tumor_samples_analyzed_by_adenosine_triphosphate_chemosensitivity_assay._We_defined_sensitivity_as_a_greater_than_or_equal_to_70%_decrease_in_intracellular_adenosine_triphosphate_versus_control_at_20%_of_the_reported_peak_plasma_concentration_per_agent_tested._Twenty_of_21_assays_(95.24%)_were_completed_successfully._Single-agent_and_combined_dose-response_patterns_consisting_of_decreasing_viability_with_increasing_drug_concentration_were_observed_consistently._Thirteen_primary_tumors_were_assayed,_with_15.4%_sensitive_to_cisplatin,_7.7%_sensitive_to_4-hydroxycyclophosphamide_and_53.8%_sensitive_to_their_combination._Seven_recurrent_tumors_were_assayed,_with_14.3%_sensitive_to_cisplatin,_28.6%_sensitive_to_5-fluorouracil,_and_42.9%_sensitive_to_their_combination._Dose-response_characteristics_and_in_vitro_sensitivity_rates_reported_in_this_article_are_consistent_with_reports_of_patient_response_in_the_literature._We_conclude_that_adenosine_triphosphate_chemosensitivity_assay_is_an_efficient_and_reliable_instrument_for_the_in_vitro_chemosensitivity_assessment_of_human_tumors_and_warrants_further_clinical_investigation.